 "Lupin to use MonoSol technology for developing paediatric products")
Lupin Ltd will use the US-based MonoSol Rx’s proprietary PharmFilm drug delivery technology to develop multiple paediatric products. A licensing agreement to this effect was signed by Lupin Pharmaceutical Inc, the US subsidiary of pharma major Lupin Limited, and MonoSol Rx yesterday.
MonoSol Rx’s PharmFilm technology is a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film. The US firm is a global leader in film-based drug delivery applications with two FDA-approved products and a robust pipeline of pharmaceuticals in development.
For patients who may have difficulty swallowing pills or tolerating medication in traditional delivery forms, PharmFilm technology provides a minimally invasive alternative to pills, injections, and gels, with the goal of helping patients adhere to their prescribed treatment regimens in order to improve their health. The technology can offer potential to support paediatric patients in particular, many of whom have difficulty with the currently available oral or injectable dosing of needed medications.
The agreement with MonoSol in line with Lupin’s focus on expanding into the specialty pharmaceutical market, and specifically, paediatric needs such as attention-deficit/hyperactivity disorder (ADHD).
“At Lupin, we are motivated by addressing urgent, unmet medical needs – and helping children and their families ensure they are able to access, tolerate and successfully take the medicines they need is a clear part of that mission. Our alliance with MonoSol Rx will enable us to expand our family of paediatric products to help meet the needs of children for a variety of indications. We look forward to working with MonoSol Rx on the development of these products,” said Paul McGarty, president, Lupin Pharmaceuticals.
Keith Kendall, CEO, MonoSol Rx, added, “We believe PharmFilm technology holds great promise for paediatric applications - enabling increased compliance and adherence in a difficult to treat population. By partnering with Lupin, whose commitment to support and expand within the paediatric and family-focused market matches our own commitment to helping paediatric patients and their families, we are taking a critical step forward in developing valuable and much-needed products.”